EUCTR2011-005738-20-GB进行中（未招募）1 期
Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Voluntarily signed and dated IRB/EC informed consent form. Written informed consent must be obtained prior to performing any study-related procedure;
- •2) Males and female subjects = 18 years of age ;
- •3) Confirmed diagnosis of ATL, excluding smoldering
- •a. Subjects must have been determined to be positive for HTLV-1 virus
- •b. Subjects must have hematologically or pathohistologically diagnosed peripheral lymphoid tissue which surface antigen analysis has identified to be of T-cell origin
- •4) Subjects must currently have evidence of disease in at least one of the following:
- •a. Lymph nodes
- •b. Extranodal masses
- •c. Spleen or liver
- •e. Peripheral blood
- •f. Bone marrow
- •5) Relapsed or refractory after at least one prior systemic therapy regimen for ATL;
- •6) Eastern Cooperative Oncology Group (ECOG) performance status score of = 2 at study entry;
- •7) The subject has resolution of all clinically significant toxic effects of prior cancer therapy to grade =1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0) excluding the specifications required in 8, 9 and 10 below;
- •8) Adequate hematological function:
- •a. absolute neutrophil count (ANC) = 1,000/mm3;
- •b. platelets = 50,000 / mm3;
- •c. If ANC and/or platelet count is less than the level specified above in the setting of documented bone marrow involvement, investigator may discuss individual case with the Medical Monitor, who will determine if subject may be enrolled
- •Note: Retesting for values out of criteria will be permitted. Subjects being recruited to this study will not necessarily meet the inclusion/exclusion criteria for baseline organ function, for investigator's choice regimens due to the leukemic nature of their illness and bone marrow involvement by the neoplastic process; this should be taken into account by the
- •investigator and if necessary discussed with the medical monitor.
- •9) Adequate hepatic function:
- •a. bilirubin = 2 times the specific institutional ULN; except for subjects with Gilbert’s Syndrome;
- •b. aspartate transaminase (AST) and alanine transaminase (ALT) each = 2.5 x ULN or = 5.0 x ULN in the presence of known hepatic ATL involvement.
- •Note: Retesting for values out of criteria will be permitted
- •10) Adequate renal function:
- •a. serum creatinine < 2 x ULN
- •b. calculated creatinine clearance > 60 mL/min using the Cockroft-Gault formula (or >30 mL/min with documented renal infiltration);
- •Note: Retesting for values out of criteria will be permitted
- •11) Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication and prior to each treatment cycle;
- •12) WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse* (periodic abstinence ,e.g., calendar, ovulation, s
排除标准
- •1) Smoldering subtype of ATL;
- •2) Lymphomatous or acute subtype subject with > 2 prior systemic therapy regimens and who has not achieved a response (CR or PR) or maintained stable disease for at least 12 weeks on last immediate prior therapy;
- •3) History of allogeneic transplant;
- •4) Autologous hematopoietic stem cell transplant within 90 days of study entry;
- •5) Untreated human immunodeficiency virus (HIV). Patients on HIV therapy with undetectable viral loads as measured by HIV RNA quantitative real time PCR may be enrolled;
- •6) Has known hepatitis C. Patients who are hepatitis C antibody positive but are hepatitis C quantitative PCR negative may be enrolled;
- •7) Has hepatitis B based on PCR testing for hepatitis B virus DNA. Patients who are hepatitis B core antibody positive but PCR negative may be enrolled if placed on appropriate anti-hepatitis B virus prophylaxis prior to commencing treatment with KW-0761. Patients who are hepatitis B core antibody positive based on prior vaccination need not receive prophylaxis;
- •8) Have had a malignancy in the past two years. However, subjects with non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current PSA of < 0.1 µg/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast with in the past two years may enroll as long as there is no current evidence of disease;
- •9) Clinical evidence of CNS involvement or metastasis.
- •10) Psychiatric illness, disability or social situation that would compromise the subject’s safety or ability to provide consent, or limit compliance with study requirements;
- •11) Significant uncontrolled intercurrent illness (as per protocol).
- •12) Subjects with a history of moderate or severe psoriasis or with psoriasis associated with systemic symptoms e.g., arthropathy, or with a 1st degree relative with history of psoriasis that required systemic medical intervention.
- •13) Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins;
- •14) Subjects randomized to the investigator’s choice treatment group may not receive a treatment they
- •have had previously or any contra-indication to any of the investigator's choice
- •regimens according to local SmPCs/Prescribing
- •Information ;
- •15) Known active autoimmune disease will be excluded. (For example; Grave’s disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn’s disease).
- •16) Is pregnant or lactating.
- •17) Prior treatment with KW-0761;
- •18) Initiation of treatment with systemic corticosteroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects (e.g., including pre-medication for infusion reaction, nausea and vomiting). Subjects on systemic corticosteroids prior to enrollment must be off for 7 days before initiation of study treatment, unless specifically indicated for the treatment of hypercalcemia. However, once the calcium returns to normal and the subject is on protocol treatment, the corticosteroid should be tapered to discontinuation as rapidly as possible. All tests to docu
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a choice of chemotherapy will work in patients with recurrent or unsuccessfully treated Adult T-Cell Lymphoma (ATL).Treatment of patients with relapsed or refractory ATLMedDRA version: 15.0Level: PTClassification code 10001416Term: Adult T-cell lymphoma/leukaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005738-20-FRKyowa Hakko Kirin Pharma, Inc.71
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a choice of chemotherapy will work in patients with recurrent or unsuccessfully treated Adult T-Cell Lymphoma (ATL).Treatment of patients with relapsed or refractory ATLMedDRA version: 17.1Level: PTClassification code 10001416Term: Adult T-cell lymphoma/leukaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005738-20-BEKyowa Hakko Kirin Pharma, Inc.70
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.Treatment of subjects with previously treated cutaneous T-cell lymphomaMedDRA version: 22.0Level: PTClassification code 10011679Term: Cutaneous T-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004766-17-DKKyowa Kirin Pharmaceutical Development, Inc.317
已完成
3 期
Study of KW-0761 Versus Vorinostat In Relapsed/Refractory CTCL.JPRN-jRCT2080222561Kyowa Kirin Pharmaceutical Development, Inc.372
进行中（未招募）
1 期
A clinical trial to test if KW-0761 (an antibody) or a chemotherapy drug, called vorinostat, will work in patients with recurrent or unsuccessfully treated Cutaneous T-Cell Lymphoma.EUCTR2012-004766-17-NLKyowa Kirin Pharmaceutical Development, Inc.317